Company news

Lantern Pharma Inc. news in 2025

Lantern Pharma Inc.'s news releases, calls and decks from 2025, newest first.

View company

Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials

December 3, 2025

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 13, 2025

Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows

November 7, 2025

Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9: 00 a.m. ET

November 6, 2025

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

October 30, 2025

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.

October 28, 2025

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025

October 24, 2025

Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

September 16, 2025

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)

September 10, 2025

Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial

September 3, 2025

RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26

August 19, 2025

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

August 13, 2025

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

August 6, 2025

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

August 4, 2025

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

July 31, 2025

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

July 28, 2025

Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

July 24, 2025

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

July 23, 2025

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

July 21, 2025

IBN Initiates Coverage of Lantern Pharma Inc.

July 16, 2025

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

July 15, 2025

Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

June 16, 2025

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

May 29, 2025

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

May 15, 2025

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

May 12, 2025

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9: 00 a.m. ET

May 8, 2025

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

May 5, 2025

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

March 27, 2025

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4: 30 p.m. ET

March 20, 2025

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

February 19, 2025

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

January 26, 2025

Calls in 2025

Decks in 2025